

Figure S1. Effective downregulation and overexpression of STING in uveal melanoma cell lines using lentiviral vector. (A) Wes Separation Protein Immunoassay of STING in downregulated (shSTING) Mel270 and Mel202 cells, compared with the scramble shRNA groups (Scramble), 55~66 and 42~59% reduction, respectively. (B) Wes Separation Protein Immunoassay of STING in overexpressing (STING⁺) Omm2.3 and Omm2.5 cells, compared with the negative control groups (Control), 29~32-fold and 15~18-fold overexpression rate, respectively. ***P<0.001. STING, stimulator of interferon genes; sh-, short hairpin.




Figure S2. Proliferation of uveal melanoma cells is not affected by the change of STING expression. (A and B) Cell viability in STING downregulated and control Mel270 and Mel202 cells at 0, 24, 48 and 72 h assessed by CCK-8 assay. (C and D) Cell viability in STING overexpressing and control Omm2.3 and Omm2.5 cells at 0, 24, 48 and 72 h assessed by CCK-8 assay. STING, stimulator of interferon genes; CCK-8, Cell Counting Kit-8; sh-, short hairpin.




Figure S3. p38-MAPK inhibitor does not affect the proliferation of uveal melanoma cells. (A and B) Cell viability in STING-downregulated and control Mel270 and Mel202 cells treated with p38-MAPK inhibitor at 0, 24, 48 and 72 h, assessed by CCK-8 assay. (C and D) Cell viability in STING-overexpressing and control Omm2.3 and Omm2.5 cells treated with p38-MAPK inhibitor at 0, 24, 48 and 72 h, assessed by CCK-8 assay. STING, stimulator of interferon genes; CCK-8, Cell Counting Kit-8; sh-, short hairpin.

